Medra AI Deploys Physical And Scientific AI To Accelerate Life Sciences Research
In Brief
Medra AI has launched its Continuous Science Platform, combining robotics and AI to automate laboratory experimentation and accelerate discoveries through collaborations with leading biotech and pharmaceutical partners.
Company specializing in autonomous robotics and AI for life sciences research, Medra AI, announced the launch of its platform designed to automate laboratory experimentation at the physical level through robotics and reasoning systems. The platform applies AI purpose-built for laboratory environments, aiming to generate larger volumes of data and facilitate scientific breakthroughs.
The system, known as the Continuous Science Platform, operates as a self-improving closed loop composed of two integrated components: Physical AI and Scientific AI. Physical AI performs actions by automating approximately 70% of laboratory instruments already in use, equipped with visual and language understanding to capture detailed data such as image records, motion logs, and precise measurements of laboratory protocols. This includes tracking specific details such as reagent mixing times and pipette angles, creating an unprecedented dataset of experimental processes at scale.
Scientific AI interprets this granular experimental data alongside real-world outcomes, producing recommendations for protocol adjustments that Physical AI then carries out. Through this iterative feedback process, both systems collaborate to refine experimental parameters and move toward optimal methodologies. Together, the components are designed to scale experimental throughput and accelerate the pace of discovery in the life sciences.
Medra AI Expands Partnerships With Biotech And Pharma To Advance AI-Driven Laboratory Research
Medra AI has established collaborations with several leading biotechnology and pharmaceutical organizations, applying its Continuous Science Platform to accelerate and enhance experimental outcomes. The platform is being used not only to increase the pace of scientific workflows but also to improve the quality and reproducibility of results.
The company has also begun publishing initial case studies with early partners. These include Addition Therapeutics, a gene-editing firm focused on RNA therapeutics where the platform is supporting RNA transfection, and Lila Sciences, a scientific intelligence platform where it is being applied to protein characterization workflows. Additional projects are underway with other partners in areas such as antibody engineering, microbial and fungal characterization, as well as cell and protein purification.
Through these initiatives, Medra AI aims to expand the role of AI-driven laboratories and provide scientists with tools to accelerate discovery and innovation across diverse fields of research.
Disclaimer
In line with the Trust Project guidelines, please note that the information provided on this page is not intended to be and should not be interpreted as legal, tax, investment, financial, or any other form of advice. It is important to only invest what you can afford to lose and to seek independent financial advice if you have any doubts. For further information, we suggest referring to the terms and conditions as well as the help and support pages provided by the issuer or advertiser. MetaversePost is committed to accurate, unbiased reporting, but market conditions are subject to change without notice.
About The Author
Alisa, a dedicated journalist at the MPost, specializes in crypto, AI, investments, and the expansive realm of Web3. With a keen eye for emerging trends and technologies, she delivers comprehensive coverage to inform and engage readers in the ever-evolving landscape of digital finance.
More articles
Alisa, a dedicated journalist at the MPost, specializes in crypto, AI, investments, and the expansive realm of Web3. With a keen eye for emerging trends and technologies, she delivers comprehensive coverage to inform and engage readers in the ever-evolving landscape of digital finance.
